Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ad26.RSV.preF Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

NCT05070546
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection Prevention
Interventions
Ad26.RSV.preF-based Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

NCT04453202
View directory record Official record
Conditions
Healthy
Interventions
RSV Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 9:18 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

NCT03982199
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Diseases
Interventions
RSV Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
5,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
40
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

NCT03339713
View directory record Official record
Conditions
Healthy
Interventions
Ad26.RSV.preF, Fluarix, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

NCT03303625
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Infections
Interventions
Ad26.RSV.preF (1*10^11 vp), Ad26.RSV.preF (5*10^10 vp), Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
12 Months to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Newton, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

NCT05071313
View directory record Official record
Conditions
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions
Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

NCT03502707
View directory record Official record
Conditions
Healthy
Interventions
Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
669 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

NCT02926430
View directory record Official record
Conditions
Healthy
Interventions
Ad26.RSV.preF 5*10^10 vp, Ad26.RSV.preF 1*10^11 vp, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

NCT05083585
View directory record Official record
Conditions
Respiratory Syncytial Virus Prevention
Interventions
Ad26.RSV.preF-based vaccine
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
San Diego, California • Lakeland, Florida • Melbourne, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

NCT04908683
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
Interventions
Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
25,236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
156
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

NCT05101486
View directory record Official record
Conditions
Respiratory Syncytial Virus Prevention
Interventions
Ad26.RSV.PreF-based Vaccine
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years to 75 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Athens, Alabama • Vestavia Hills, Alabama • Phoenix, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 2, 2026, 9:18 PM EDT